8-K
filed May 29, 2026, 4:35 PM ET
ticker KNSA
CIK 0001730430
other
confidence high
sentiment neutral
materiality 0.15
Kiniksa shareholders re-elect all three Class II directors and approve all eight proposals at 2026 annual meeting
Kiniksa Pharmaceuticals International, plc
- Stephen R. Biggar re-elected with 37.5M for, 12.0M against; G. Bradley Cole and Barry D. Quart each received ~48.3M for.
- PricewaterhouseCoopers LLP approved as both UK statutory auditor and US independent auditor with overwhelming votes.
- Advisory vote on named executive officer compensation passed with 48.1M for and 1.3M against.
- All eight proposals, including director elections, auditor appointments, and remuneration reports, were duly passed.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kiniksa Pharmaceuticals International, plc shareholders approved Receive UK statutory annual account and report for period ended December 31, 2025 at the 2026-05-29 meeting.
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
Proposal 5 - To receive the Company’s UK statutory annual account and report for the period ended December 31, 2025.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kiniksa Pharmaceuticals International, plc shareholders approved Ratify appointment of PwC as US independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-29 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
Proposal 3 - To ratify the appointment of PwC as the Company’s US independent registered public accounting firm for the fiscal year ending December 31, 2026.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kiniksa Pharmaceuticals International, plc shareholders approved Re-election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors at the 2026-05-29 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
Proposal 1 - The re-election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors to serve on the Board of Directors until the 2029 Annual Meeting of Shareholders
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kiniksa Pharmaceuticals International, plc shareholders approved Approve UK Statutory Directors’ Remuneration Policy at the 2026-05-29 meeting.
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
Proposal 7 - To approve the Company’s UK Statutory Directors’ Remuneration Policy.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kiniksa Pharmaceuticals International, plc shareholders approved Authorize board of directors, through audit committee, to determine PwC’s remuneration as UK statutory auditors at the 2026-05-29 meeting.
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
Proposal 4 - To authorize the Company’s board of directors, through its audit committee, to determine PwC’s remuneration in its capacity as the Company’s UK statutory auditors until the close of its next Annual Meeting of Shareholders.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kiniksa Pharmaceuticals International, plc shareholders approved Advisory approval of compensation of named executive officers at the 2026-05-29 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
Proposal 8 - To approve, on an advisory non-binding basis, the compensation of the Company’s named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kiniksa Pharmaceuticals International, plc shareholders approved Appointment of PricewaterhouseCoopers LLP as UK statutory auditors at the 2026-05-29 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
Proposal 2 - To approve the appointment of PricewaterhouseCoopers LLP (“PwC”) as the Company’s UK statutory auditors until the close of the Company’s next Annual Meeting.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kiniksa Pharmaceuticals International, plc shareholders approved Advisory approval of UK Statutory Directors’ Annual Remuneration Report for period ended December 31, 2025 at the 2026-05-29 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
Proposal 6 - To approve, on an advisory non-binding basis, the Company’s UK Statutory Directors’ Annual Remuneration Report for the period ended December 31, 2025.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.